Listen Now

A retrospective, multicenter, observational, database analysis conducted to quantify rates of organ-specific dysfunction in individuals with COVID-19 after discharge from hospital compared with a matched control group from the general population

A randomized, open-label, trial conducted to evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).

A retrospective, observational, cohort study conducted to compare the rate of change in estimated glomerular filtration rate (eGFR) after hospital discharge between patients with and without COVID-19 who experienced in-hospital acute kidney injury (AKI)

A randomized study conducted to determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) viral load in mild to moderate COVID-19

A controlled, open-label trial conducted to report the results of the controlled, open-label Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial of dexamethasone in patients hospitalized with COVID-19.

A randomized multicenter, double-blind, parallel-group, placebo-controlled trial, conducted to investigate the effect of vitamin D3 administration on hospital length of stay and other relevant clinical outcomes and adverse events in hospitalized patients with moderate to severe COVID-19. 

A randomized, multi-center, open-label, open-label, factorial clinical trial conducted to examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection. 

Early data suggests the incidence of true anaphylaxis to the Pfizer-BioNTech COVID-19 vaccine is rare (11.1 cases per million vaccine doses). Anaphylaxis is more common in women and persons with a history of allergies, and symptoms typically appear within 30 minutes of injection.

A retrospective, observational, cohort study done to assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19.

A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein

An observational cohort study performed to describe characteristics and outcomes of hematopoietic stem-cell transplantation (HSCT) recipients after developing COVID-19

A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.

A cohort study done to comparatively examine differences in risk of clinical manifestations and death among people admitted to hospital with coronavirus disease 2019 (COVID-19) and seasonal influenza.

A phase 3 randomized, stratified, observer-blinded, placebo-controlled trial to to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. 

A randomized, multicenter, adaptive, double-blind, placebo-controlled trial to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.

A comparative study done to evaluate the fitted filtration efficiency (FFE) of various consumer-grade and improvised face masks, as well as several popular modifications of medical procedure masks that are intended to improve mask fit or comfort.

A case report describing two monozygotic twins with different clinical courses, despite having the same environment and genomic factors. 

A retrospective, cohort study conducted to determine the adjusted effect of body mass index (BMI), associated comorbidities, time, neighborhood-level sociodemographic factors, and other factors on risk for death due to COVID-19

A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19. 

The purpose of this study was to evaluate the efficacy and safety of LY-CoV555 (bamlanivimab) in patients with recently diagnosed mild or moderate COVID-19 in the outpatient setting